Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].

Published

Journal Article

Full Text

Duke Authors

Cited Authors

  • Choueiri, TK; Hessel, C; Halabi, S; Sanford, B; Michaelson, MD; Hahn, O; Walsh, M; Olencki, T; Picus, J; Small, EJ; Dakhil, S; Feldman, DR; Mangeshkar, M; Scheffold, C; George, D; Morris, MJ

Published Date

  • November 2018

Published In

Volume / Issue

  • 103 /

Start / End Page

  • 287 -

PubMed ID

  • 30270112

Pubmed Central ID

  • 30270112

Electronic International Standard Serial Number (EISSN)

  • 1879-0852

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2018.09.022

Language

  • eng

Conference Location

  • England